Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Previous post Buy FedEx’s stock on the big dip, analyst says
Next post Not sure what to do with your 401(k)? Let these smart people help you.